Rhythm Pharmaceuticals, Inc. (RYTM) EPS Estimated At $-0.45 on June, 11

May 17, 2018 - By Michael Garrison

On June, 11 WallStreet awaited Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)’s earnings release, Zacks reports. 9.76 % negative EPS growth is what Wall Street’s sees after $-0.41 reported EPS previous quarter. The stock increased 3.15% or $0.94 during the last trading session, hitting $30.78.Rhythm Pharmaceuticals, Inc. is after having 0.00% since May 17, 2017. RYTM has 145,865 volume or 44.87% up from normal. RYTM underperformed by 11.55% the S&P500.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States.The company has $847.00 million market cap. The Company’s lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alstr??m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.Last it reported negative earnings. The firm was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.

More recent Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) news were released by Nasdaq.com, Nasdaq.com and Globenewswire.com. The first one has “Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference” as a title and was released on May 09, 2018. The next is “Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of …” on May 09, 2018. And last was released on May 14, 2018, called “Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results”.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.